- The Phase III trial AV001 aims to evaluate QUTENZA® in post-surgical neuropathic pain (PSNP), a debilitating complication of surgery occurring after approximately 10 percent of all surgical ...
The Phase III trial AV001 aims to evaluate QUTENZA in post-surgical neuropathic pain (PSNP), a debilitating complication of surgery occurring after approximately 10 percent of all surgical procedures ...
TRV045 is a novel, highly selective sphingosine-1-phosphate subtype 1 (S1P 1) receptor modulator being developed as a potential treatment for acute and chronic neuropathic pain secondary to diabetic ...
On Wednesday, Sonnet’s stock saw a dramatic rise, making it one of the most talked-about biotech stocks of the day. This uptick comes in the wake of a key announcement from the company: the issuance ...